CD274 and neoplasm: However, biomarkers for ICI monotherapy, including intratumoral PD‐L1 expression, single gene mutations, tumor mutational burden, or frameshift indel load, have been demonstrated to be unreliable for predicting the TKI + IO benefits of mRCC.7, 8, 9